Vaxcyte, Inc. is a clinical-stage biotechnology company that develops vaccines to protect against bacterial diseases. The company's pipeline is led by its pneumococcal conjugate vaccine (PCV) franchise, which includes VAX-31, a 31-valent candidate in Phase 3 trials for adults, and VAX-24, a 24-valent candidate for infants. Vaxcyte is also advancing VAX-A1 for the prevention of Group A Strep infections and VAX-GI for Shigella. A key operational characteristic of the company is its use of the XpressCF cell-free protein synthesis platform, which enables the production of complex proteins and antigens outside of conventional cell-based manufacturing approaches. Headquartered in San Carlos, California, Vaxcyte aims to provide broader serotype coverage than currently available standard-of-care pneumococcal vaccines.
